Macrophages hold a critical position in the pathogenesis of liver injury and repair, in which their infiltrations is regarded as a main feature for both acute and chronic liver diseases. It is noted that, based on the distinct phenotypes and origins, hepatic macrophages are capable of clearing pathogens, promoting/or inhibiting liver inflammation, while regulating liver fibrosis and fibrolysis through interplaying with hepatocytes and hepatic stellate cells (HSC) via releasing different types of pro-or anti-inflammatory cytokines and growth factors. Macrophages are typically categorized into M1 or M2 phenotypes by adapting to local microenvironment during the progression of liver injury. In most occasions, M1 macrophages play a pro-inflammatory role in liver injury, while M2 macrophages exert an anti-inflammatory or pro-fibrotic role during liver repair and fibrosis. In this review, we focused on the up-to-date information about the phenotypic and functional plasticity of the macrophages and discussed the detailed mechanisms through which the phenotypes and functions of macrophages are regulated in different stages of liver injury and repair. Moreover, their roles in determining the fate of liver diseases were also summarized. Finally, the macrophage-targeted therapies against liver diseases were also be evaluated.
Introduction
In the liver, the ongoing wound healing and unresolved liver injury can lead to liver fibrosis, which is the major cause of liver-related morbidity and mortality [1] . The tissue in the injured liver shows liver cell cord derangement, intercellular spaces dilatation and inflammatory cell infiltration [2] . Moreover, the liver can also be quite capable of repairing and regenerating. The tissue in the repaired liver shows elimination of inflammation, tissue debris and apoptotic bodies, as well as the induction of angiogenesis [3] . However, the ongoing wound healing and unresolved liver injury can lead to liver fibrosis and when comes to liver fibrolysis, macrophages can also reduce extracellular matrix (ECM) and exert anti-inflammatory roles [4] .
Macrophage, a type of the mononuclear phagocytes, is believed to contribute to tissue integrity and repair [1, 5] . Moreover, evidence has now accumulated showing that macrophages hold a critical position in the pathogenesis of liver injury and repair. They play a key role in regulating many organ systems including systemic metabolism, innate immunity, malignancy, hematopoiesis and reproduction [6] . Macrophages can be activated and polarized into different types in response to local microenvironment. The diverse functions of macrophages include clearance of pathogens, promoting liver fibrosis by activating HSC in chronic liver damage, as well as resolving fibrosis or inflammation by degrading extracellular matrix or releasing of different types of anti-inflammatory cytokines and growth factors [7] .
In this review, we focus on the updated information about the phenotypic and functional plasticity of the macrophages. We also touch upon the regulatory mechanisms in different stages of liver injury and repair. Additionally, we highlight the relevant therapies which can target the dual function of macrophages and try to open up new possibilities for therapeutic interventions [8] .
Activation and polarization of macrophages in liver injury
In the liver injury, macrophages are highly plastic and heterogeneous in most occasions. The origin of macrophages is either circulating monocytes, which can be recruited to the injured liver via growth factors and chemokine signals, or self-renewing embryo-derived resident macrophages, called Kupffer cells (KC) [9] . It is well identified that most of resident macrophages, including KC, are derived from progenitor cells generated during development in the yolk bag and foetal liver [10, 11] . Lines of evidence show that resident macrophages maintain themselves by self-renewal instead of transforming from blood-born monocytes [12] . The other macrophage system origins from HSC and is based on definitive hematopoiesis.
The role of macrophages in liver injury remains controversial because of its heterogeneity [13] . Macrophage heterogeneity and plasticity are characterized by a high diversity of cell surface markers and transcriptional profiles, different self-local environment-derived stimuli which could induce the polarization of macrophage phenotypes [14, 15] .
In most occasions, the classification and definition of M1/M2 macrophages is widely used [16] . Macrophages have been categorized either into 'pro-inflammatory' M1 or 'anti-inflammatory' M2 macrophages depending on a high diversity in the release of cytokines, cell surface markers and different transcriptional profiles [17] . These so-called M1 macrophages are classic activated macrophages which are characterized by secretion of pro-inflammatory cytokines such as IL-6, TNF-a, IL-1, IL-12, IL-15 and IL-18 [18] . They are also capable to recruit other immune cells by releasing chemokines including CXCL9, CXCL10 and CXCL11 as well as CCL15 and CCL20. Furthermore, they are prone to serve as the innate effector cells by synthesizing reactive oxygen species (ROS) and nitric oxide (NO) [2, 10] . In contrast, alternatively activated macrophages, which are also called M2 macrophages, can be polarized by IL-4 and IL-13 [19] . Compelling evidence reveals that M2 macrophages could be further subcategorized by their distinct stimuli. For instance, M2a macrophages can be induced by IL-4 plus IL-13; M2b macrophages can be induced by immune complexes, and M2c subtype is induced by IL-10 plus transforming growth factor (TGF)-b, which mirror the Th1/Th2 polarization and mediate Th1/Th2 immune response [20] . M2a or M2c phenotypes can suppress both inflammation and fibrosis and M2c cells showing their ability to induce the production of other immune cells like immune-suppressing regulatory T cells [21] . (Table 1) .
Moreover, besides the M1/M2 classification, it was reported that different Ly6c expression has been widely used to characterize the populations of circulating monocytes and macrophage in pathology. Ly6c is a cell surface glycoprotein to distinguish the circulating monocyte populations. Two populations of the circulating monocytes, including Ly6c + and Ly6c -monocytes, are well defined. Meanwhile, several lines of evidence indicate that the Ly6c high and Ly6c low macrophage subsets are derived from recruited Ly6c high monocytes [22] . The Ly6c high macrophages are thought to be pro-inflammatory, which mirror the M1 macrophages, while the Ly6c low macrophages also acquire an M2-like phenotype which can play an anti-inflammatory role during the liver injury [23] . In the diseased liver, the chemokine receptor interactions also have an impact on the infiltration of macrophages. For instance, the chemokine receptor interactions CCL2/CCR2 or CCL1/CCR8 could influence the percentage of proinflammatory Ly6c high macrophages [24] . Moreover, it is interesting that the M3 switch phenotype is detected recently in lung diseases besides the M1 and M2 macrophages phenotypes. The study have hypothesized that an M3 switch phenotype responds to anti-inflammatory stimuli with reprogramming towards the proinflammatory M1 phenotype or on the contrary, it responds to pro-inflammatory stimuli with reprogramming towards the anti-inflammatory M2 phenotype. The switch during the M1 and M2 relied on the information delivered by M3 switching phenotype [25] . Hence, our understanding of the phenotype of macrophages is inadequate, and the polarization and phenotype switch of the macrophages in liver still need to be extensively explored.
Macrophages in liver injury
It is well accepted that macrophages can not only maintain the tissue integrity under the different conditions, but also destroy the tissues by releasing abundant pro-inflammatory factors and chemokines when inflammation is uncontrolled. Indeed, it has been reported that the functional macrophages subsets in liver injury mainly depend on their origins [26] . As referenced, the origin of macrophages is either circulating monocytes or resident macrophages.
Kupffer cell (KC)
As we know, resident macrophages have been regarded as KCs in the liver in many conditions. Recent data confirmed that regulation of the functional phenotype of KCs was linked with the progression of many liver diseases, including alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), acute liver injury (ALI), alcoholic hepatitis (AH), acute liver failure (ALF) and hepatocellular carcinoma (HCC) [27, 28] . In addition, another study demonstrated that Kruppel-like factor 4 (KLF4) can promote the polarization of KCs towards M1 phenotype, therefore increasing the severity of alcoholic liver disease (ALD) [29] .
In this regard, several lines of evidence show that M1 KC are capable of secreting pro-inflammatory factors including TNF-a, IL-6, reactive oxygen species (ROS) and inducible NO synthase (iNOS) which may induce liver damage [14] .
In addition, another study has also identified KCs as vital mediators of NAFLD and NASH. For instance, liposomal clodronate-induced KC depletion in a high-fat diet mouse model results in the reversal of the hepatic steatosis [30] . At the early stage of ALF, the M1 KCs are activated by TNF-a and IFN-c and they play the hepatotoxic role in the liver. Previous studies also paid attention to the interaction between the M1 KC and M2 KC in the liver disease [31] . It is well documented that M2 KC may trigger the M1 KC apoptosis in the ALD and NAFLD. Promoting M2-induced M1 KC apoptosis may have a strong impact on limiting ALD and NAFLD inflammation and hepatocyte injury, whereas this mechanism has been undefined and still need to be extensively explored [30] . For example, KCs interplay with hepatocytes to regulate hepatic triglyceride storage. KCs have a great effect on the liver triglycerides by suppressing PPAR-c expression and activity [32] .
To conclude, the orchestration of M1 KC function plays a key role in different pathological conditions. Better understanding of M1 KC is essential because the M1 KC can provide a basis for the development of uncontrolled KC-targeted therapeutic strategies [15] .
Circulating monocytes
In addition to the KCs, the circulating monocytes originating from hematopoietic stem cells also have a critical impact on the liver injury. They have been recruited to tissues in homoeostasis and injury-associated inflammation which hold an important position in liver injury [33, 34] .
Identified recent study shows that circulating Ly6C high monocytes were recruited in a CCR2-and M-CSFdependent manner and eventually resulted in the tissue inflammation in ALI by adoptive transferring purified BMderived CD45.1 Cx3cr1 gfp/+ Ly6C high monocytes into APAP-challenged wild-type recipients [35] . Generally, the circulating monocytes have two main subsets including patrolling monocytes (CX3CR1 high Ly6C -in mouse) and inflammatory monocytes (CCR2 high Ly6C + in mouse). This population can be recruited at inflammatory sites by specific chemokines such as CCL2 [23] . In the primary biliary cirrhosis (PBC) patients, number of circulating CD16 + monocytes increased at the early stage. Therefore, we speculated that the CD16 + monocytes may contribute to advanced liver cirrhosis. It was reported that the circulating CD14 low CD16 + monocytes participates in the liver inflammation and injury by secreting amounts of costimulatory molecules (including HLA-DR and CD80) and IL-12 [36] .
In summary, the M1 phenotype of pro-inflammatory macrophages can aggravate liver injury in the most time through mechanisms listed as follow: (1) secreting abundant pro-inflammatory cytokines and chemokines to activate and increase inflammatory response [25, 27, 37] ; (2) generating reactive oxygen species (ROS) to induce the apoptosis of hepatic cells, therefore boosting the progression of liver injury [38] . In addition to the contents abovementioned, the mechanisms of M1 macrophages-mediated liver injury are complicated and need to be extensively explored.
Activation and polarization of macrophages in liver repair
As we know, the liver can be quite capable of repairing and regenerating. It is of note that M2 macrophages are regarded as critical mediator in the liver repair.
Kupffer cell (KC)
During the repair phase of liver, the M2 KCs release antiinflammatory cytokines like IL-10 to play an important role in the tissue remodelling, elimination of inflammation, tissue debris and apoptotic bodies, as well as the induction of angiogenesis. Using a murine model in which M2 KCs could be depleted, Chu et al. [35] demonstrated that the absence of M2 KCs delayed the liver repair in the acetaminophen (APAP)-induced liver injury (AILI). Besides, they also found that the M2 KCs have an important role in liver blood vessel repair and can also compensate for the lack of circulating cells. Another study points out that infiltration of macrophage following acetaminophen-induced acute liver failure (AALF) is associated with the resolution of inflammation and tissue repair processes. In the ALD, cannabinoid CB2 receptors are reported to inhibit the M1 polarization and promote the transition of macrophage to an M2 phenotype. In addition, it has been reported that preventing the polarization of M1 to M2 in ALD may lead to the progressive liver inflammation and injury [39] . Compelling evidence also illustrates that some cytokines could be mediated by the M2 KC. For example, the mice lack of early growth response-1 (Egr-1) are protected from both chronic alcoholic liver injury and LPS-induced inflammation. This regenerative response is associated with hepatoprotective mediators by M2 KC [40] . As is same to the M1 KC, the M2 KC also has a vital influence in liver tissue remodelling by interacting with other cells. For instance, the M2 KCs interplay with bona fide stem cell or progenitor cells and contribute to liver repair [41] .
In general, the M2 KC joins in polarized Th2 responses, including clearance of parasite, inhibition of inflammation and acceleration of tissue repair.
Circulating monocytes
As we know, the circulating monocytes also act as effective mediators in the tissue restoration and remodelling after liver injury in addition to the M2 KC [42] .
It is well documented that monocytes expressing Ly6C À CCR2 À CX3CR1 high are found in both damaged and healthy tissues, and their function is usually connected with an anti-inflammatory and reparative phase [43] . The switch from M1 to M2 phenotype of recruited monocytes has been observed in different model of ischaemic liver [41] . Using distinct macrophage depletion and adoptive transfer techniques, the role of circulating monocytes was evaluated in many experimental liver disease models. For instance, in the acetaminophen (APAP)-induced liver injury (AILI), it causes recruitment of circulating monocytes in CCR2-dependent manner. It was demonstrated that the absence of infiltrating macrophages in CCR2 À/À mice may lead to delayed tissue remodelling post-ALI [44] . [45] .
Although both the M2 KC and circulating monocytes are critical for the wound healing process, the failure of macrophages to switch from M1 to M2 phenotype and ongoing accumulation of M2 macrophages may initiate liver fibrosis [46] (Fig. 1) .
In summary, the M2 phenotype of recruited monocytes developed the anti-inflammatory in liver tissue repair, but the mechanisms have not been inadequate and need extensively explored [47] .
Macrophages in liver fibrosis and fibrolysis
Liver fibrosis is defined by progressive accumulation of extracellular matrix (ECM) which can enrich in fibrotic collagens and a failure of ECM turnover. This process is driven by a heterogeneous population of the myofibroblasts, which primarily origin from HSC and resident fibroblasts [48] . As shown in Fig. 1 , ongoing wound healing and unresolved liver injury can lead to liver fibrosis. It is well documented that hepatic macrophages play an important role in liver fibrosis by perpetuating an inflammatory phase leading to the abundant release of proinflammatory cytokines and chemokines as well as the activation of HSC, which implies the pro-fibrotic property of hepatic macrophages in various liver diseases [47, 48] . For instance, the depletion of macrophage in the progression of liver fibrosis resulted in attenuating renal fibrosis. Moreover, inhibiting macrophages infiltration using a mutated form of monocyte chemoattractant protein-1 (MCP-1) could also attenuate renal fibrosis [49, 50] . It has been reported that the number of macrophages is associated with increased expression of pro-fibrotic cytokines and transforming growth factor b 1 (TGF-b 1 ), which is further evidenced by the findings that elimination of macrophages in the progressive phase inhibits liver fibrosis by blocking the TGF-b 1 expression [51] . In addition, large amounts of M2 macrophages can be detected in the fibrotic area of CCl 4 -treated (150 ll/100 g body weight in paraffin oil 1:1) liver fibrosis murine models and are strongly correlated with the severity of fibrogenesis [52, 53] . In conclusion, hepatic macrophages participate in the progression of liver fibrosis by several mechanisms as follows:
(1) the macrophages could release abundant chemokines and cytokines factors like matrix metalloproteinase-9 (MMP-9), TGF-b 1 , vascular endothelial growth factor (VEGF) and angiotensin II which can accelerate the activation of hepatic resident cells [54] . (2) The M2 macrophages can secrete lots of pro-fibrotic factors, such as TGF-b 1 , vascular endothelial growth factor (VEGF) and galectin-3, thus promotes myofibroblasts proliferation and activation, which can lead to the deposition of ECM. (3) The activated macrophages have the capacity to destroy hepatic vascular architecture, thereby triggers the hypoxiainduced liver fibrosis [55] . Numerous studies have demonstrated that accumulation of ECM during liver injury is caused by accumulation of myofibroblasts in the process of hepatic injury. The origin of myofibroblasts is mainly from the HSC and portal fibroblasts, in addition to extrahepatic precursors [56] . It has been illustrated that HSC may transdifferent into myofibroblastic phenotype identified by overproduction of a-smooth muscle actin (a-SMA) as well as chemotactic, fibrogenic and mitogenic factors during liver fibrosis. Meanwhile, portal fibroblasts play a vital role in the progression of liver fibrosis during biliary and cholestatic liver diseases. In addition to the above, another study demonstrated that macrophages not only enhance myofibroblasts survival but also may suffer transdifferentiation towards myofibroblasts directly, suggesting the macrophages-myofibroblasts transition may be the one of the mechanisms by which inflammatory macrophages promote liver fibrosis although the underlying mechanisms remain largely explored [57] . + monocytes can be accumulated in inflamed human liver and their phagocytic effect and the capacity to release inflammatory and pro-fibrotic cytokines, suggesting that they play a vital role in liver fibrosis [58] .
However, the experimental reversible murine models indicate that monocytes/macrophages are not only important to fibrosis but also to fibrolysis because macrophages/ monocytes can also reduce ECM and exert anti-inflammatory roles [59] . It is identified that monocytes/macrophages may contribute to the regression of liver fibrosis by releasing matrix metalloproteinase (MMPs) which can degrade the ECM in the fibrotic liver. For instance, selective depletion of macrophages by diphtheria toxin receptor in a transgenic mouse model after CCl 4 -induced injury delayed the resolution of fibrosis, which may be attributed to downregulation of matrix metalloproteinase-13 (MMP-13) which plays key role in degrading ECM proteins [60] . Moreover, another study provides the evidence that macrophage-derived matrix metalloproteinase-12 (MMP-12) can also regulate the degradation of elastin, which is predominant in ECM components [61] . Besides MMPs, many reports have documented that the suppression of tissue inhibitor of metalloproteinases (TIMPs) can promote liver fibrolysis by eliminating myofibroblasts via apoptosis or reversing them towards a quiescent phenotype, as deactivation of HSC is also a key step during the regression of fibrosis [62] . Evidence for the positive regulatory role of macrophages in liver fibrolysis has been collected in CCl 4 -induced experimental reversible models. It has been proposed that the activated KC can induce HSC death via caspase-9 and possibly involving tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) [63] . Of note, the exact phenotype of macrophages/monocytes during fibrosis regression is still not fully characterized although a recent study proposed that monocyte-derived myeloid dendritic cells can facilitate liver fibrosis regeneration using adoptive transfer [64] .
In addition to the above, several lines of evidence have revealed that interactions between fibrotic cells and other hepatic cells or progenitor cells may also correlated to fibrogenesis during the regression of liver fibrosis. Activated HSC also secrete anti-proliferative signals for hepatic cells like TGF-b 1 , which may suppress liver regression but also has a capacity to promote liver fibrosis. For example, it has been reported that the serotonin receptor (5-HT2B) in activated HSC may combine pro-fibrotic properties with TGF-b 1 -promoted anti-proliferative properties towards hepatocytes during the liver fibrolysis [49, 65] .
Regulatory mechanisms of macrophage polarization in liver diseases
Macrophage polarization is controlled by different molecular mechanisms, which include signalling pathways, transcription factors, posttranscriptional regulators, epigenetic regulation and so on [66] . It has been reported that several classic regulatory pathways and factors including JNK, PI3K/AKt, Notch, JAK/STAT, NF-jB signalling pathways may play critical role in the macrophages polarization, which is discussed below [67] .
For instance, selective depletion of JNK in macrophages attenuated the degree of high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD), which indicated that JNK may contribute to M1 macrophages polarization [68] . Many reports have been demonstrated that the activation of PI3K signalling pathways can regulate many aspects of cellular activity such as metabolism, motility, proliferation and so on [69] . Akt is known to be an important effector of PI3K, and it has been reported that Akt may play a crucial role in macrophages polarization. Akt1, one of the Akt kinases, has been confirmed to promote M1 macrophages polarization. Meanwhile, an Akt1-mediated, microRNAinvolved regulatory mechanism underlying pathogendriven macrophage polarization was also shown by a recent study, which described that Akt was activated by LPS, positively and negatively by different miRNAs. For example, PI3K/AKt signalling pathway was positively regulated by miRNA-181c and negatively regulated by miRNA-155 [70, 71] . In respect to the Notch signalling pathways, previous studies indicated that blocking of Notch signalling with GSI or RBP-J knockout eliminated LPS-induced expression of suppressor of cytokine signalling-3 (SOCS-3), which suggested that SOCS-3 was a downstream molecule to Notch signalling pathways to mediate the polarization of macrophages [72] . Moreover, Xu et al. [73] demonstrated that Conditional Notch1 deficiency attenuated M1 macrophages activation and inflammation in a murine model of alcoholic steatohepatitis (ASH). In mouse and human fibrotic livers, Notch signalling pathway components were found to be upregulated in TGF-b-activated HSC and inflammatory M1 macrophages significantly. Further understanding of the roles of Notch signalling pathways playing in specific cancer types may provide a rationale for novel Notch-based therapeutic strategies. Hence, the results proposed some new therapies for many liver diseases through the modulation of macrophage polarization through targeting Notch signalling pathways [75, 76] . In the JAK/STAT signalling pathways, there are four different types of members in JAk family including JAk1, JAk2, JAk3 and Tyk2, and seven STATs including STAT1, STAT2, STAT3, STAT4, STAT6 and two STAT5 genes. They have different impacts on polarization of macrophages [77, 78] .
Accumulating data showed that the activation of macrophages phenotypes was regulated by cytokines via JAK/ STAT signalling pathway. For instance, IFN-c induced the M1 macrophage polarization by activating STAT1 predominantly, which indicated the activating function of IFN-c, such as capacity to enhance inflammatory cytokine production [79] . Moreover, SOCS proteins have been described as inhibitors of JAK/STAT signalling pathway. A recent study demonstrated that SOCS-3-deficient macrophages had higher levels of M1 markers like IL-1b, IL-6 and iNOS [72] . Moreover, it is also identified that the over-expression of SOCS-3 induces M1 macrophages activation of co-cultured macrophages, indicating its role in mediating polarization of macrophages through JAK/ STAT signalling pathways [80, 81] . In addition, NF-jB signalling pathway is considered to play a crucial role in M1 macrophage polarization. The recent study found that p21-activated kinase-1(PAK1) was induced in macrophages in response to inflammatory stimuli, which may promote M1 macrophage polarization via PAK1-dependent NF-jB activation. Moreover, blockade of NF-jB activation with its natural inhibitor IjB can suppress NFjB activity and TNF-a production mediated by PAK1 activation [82, 83] .
Besides, epigenetic regulators and noncoding RNAs can be also involved in the regulation of macrophages polarization. For example, histone deacetylase 3 (HDAC3) has been characterized as an epigenetic accelerator and suppressor for M2 macrophage polarization. Meanwhile, microRNAs (miRNAs) including miR-155, miR-147, miR-187, miR-124 and let-7c were also identified as different mediators of macrophages polarization [84, 85] .
Macrophage-targeted therapy for liver diseases
There are two sides in the macrophage-based therapies in liver injury. On the one hand, macrophages serve as a therapeutic target in liver diseases. On the other hand, macrophages may act as a therapeutic agent for treating liver diseases [74] .
It has been well documented that inhibition of macrophages infiltration or monocytes recruitment can reduce the liver inflammation, therefore attenuating liver injury efficiently. For instance, administration of CX3CL1 to induce a protective M2 phenotype could effectively reduce liver damage [80, 86] . It has been reported that silencing TNF-a gene or treatment with neutralizing anti-TNF-a antibodies in KCs protected against acute liver failure (ALF), which further supported the critical role of TNF-a in macrophage-associated mediator of ALF [87] .
Although using liposomal clodronate to suppress macrophages is widely used in the current experiment and has capacity to reduce liver inflammation, it is less specific [62, 81] . Furthermore, it has been reported that KC-specific inhibition of NF-jB using decoy oligonucleotides displayed a therapeutic effect at the early stage of ALF, even applied to experimental animal models with more severe injury like liver ischaemia-reperfusion model. In addition, the study in clinical experiments has shown that transcatheter arterial steroid injection therapy (TASIT) could help to relieve ALF patients by suppressing the activation of macrophages specifically [88] .
Modification of the macrophage phenotype has also been applied to inhibit liver diseases in a series of studies. For instance, a recent study demonstrated that IL-4 upregulated the histone demethylase-dependent chromatin modifications in liver macrophages to promote expression of M2 markers while inhibiting M1 markers, thereby significantly reduces liver inflammation [13] . In addition, the liver-derived histidine-rich glycoprotein (HRG) was demonstrated in mouse tumour models to mediate the transition of M2 phenotype towards M1 phenotype which limit tumour growth and metastasis. In this regard, controlling tissue levels of HRG or PGF might be a promising strategy to treat chronic inflammatory liver diseases [89, 90] .
Conclusion and perspective
In conclusion, macrophages can be activated and polarized into different types in response to local microenvironment after being recruited into the injured liver. The activated macrophages can not only maintain the tissue integrity under the different conditions but also destroy the tissues through releasing abundant pro-inflammatory factors and chemokines in different liver diseases. M1 macrophages trigger liver injury at an early stage, while M2 macrophages reduce liver inflammation and accelerate liver repair during the late stage of liver injury. However, ongoing wound healing and unresolved liver injury can lead to liver fibrosis in the phase of liver repair. In this regard, how to suppress the M1 phenotype, but promote M2 phenotype polarization may become the hotspot in the treatment of liver diseases in the future.
In this review, the relevant therapies for liver diseases targeting macrophage recruitment, activation, polarization and phenotype switch need to be extensively investigated and hope to open up the new avenues of therapeutic intervention in the future.
